Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lyra Therapeutics Inc
(NQ:
LYRA
)
0.1900
-0.0083 (-4.19%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lyra Therapeutics Inc
< Previous
1
2
3
Next >
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 14, 2024
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
June 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 07, 2024
Via
Benzinga
Where Lyra Therapeutics Stands With Analysts
May 07, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
May 07, 2024
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday!
Via
InvestorPlace
What 4 Analyst Ratings Have To Say About Lyra Therapeutics
October 06, 2023
Via
Benzinga
Lyra Therapeutics: Q1 Earnings Insights
May 12, 2023
Via
Benzinga
Lyra Therapeutics's Return On Capital Employed Insights
March 30, 2023
Via
Benzinga
Lyra Therapeutics: Q2 Earnings Insights
August 09, 2022
Lyra Therapeutics (NASDAQ:LYRA) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
May 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
May 06, 2024
Via
Benzinga
Exposures
Fossil Fuels
12 Health Care Stocks Moving In Monday's Intraday Session
May 06, 2024
Via
Benzinga
DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges
May 06, 2024
Trump Media & Technology stock is up on Monday as DJT investors react to the company naming a new auditor as its old one faces SEC charges.
Via
InvestorPlace
Topics
Government
Regulatory Compliance
Exposures
Legal
Political
Regulatory
ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range?
May 06, 2024
Zeekr is planning an IPO this week that will have the Chinese EV company pricing shares of ZK stock between $18 and $21 per share.
Via
InvestorPlace
Topics
Initial Public Offering
Exposures
Securities Market
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
May 06, 2024
Via
Benzinga
Topics
Earnings
Exposures
Financial
Warren Buffett Just Gave Up on Paramount (PARA) Stock
May 06, 2024
Paramount Global stock is on the move Monday after Warren Buffett revealed he sold all of the PARA shares owned by Berkshire Hathaway.
Via
InvestorPlace
Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today?
May 06, 2024
Lyra Therapeutics stock is falling hard with heavy trading on Monday after the company reported a failed Phase 3 clinical trial.
Via
InvestorPlace
Why Lyra Therapeutics Stock Is Down 93% Today
May 06, 2024
Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
Via
Benzinga
LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024
April 30, 2024
LYRA stock results show that Lyra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023
March 21, 2024
LYRA stock results show that Lyra Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
Via
InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 12, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2023
August 31, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 26, 2023
Via
Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
March 27, 2023
On Monday, 89 stocks made new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
December 08, 2022
During Thursday's trading, 138 companies set new 52-week lows.
Via
Benzinga
Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary
September 13, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
November 30, 2022
During Wednesday's session, 107 stocks hit new 52-week lows.
Via
Benzinga
Lyra's Mid-Stage Chronic Rhinosinusitis Candidate Study Progressed, Shares Fall
September 13, 2022
Lyra Therapeutics (NASDAQ: LYRA) advanced into its Part 2 of the Phase 2 BEACON clinical trial of LYR-220 in adults with chronic rhinosinusitis (CRS) who have had a prior sinus surgery.
Via
Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.